{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["North ML"],"pubmed_abstract":["<h4>Background</h4>Oral antihistamines that target the histamine receptor-1, such as fexofenadine, offer suboptimal relief of allergic rhinitis-associated nasal congestion. Combinations with oral sympathomimetics, such as pseudoephedrine, relieve congestion but produce side effects. Previous animal and human studies with histamine receptor-3 antagonists, such as PF-03654764, demonstrate promise.<h4>Methods</h4>Herein we employ the Environmental Exposure Unit (EEU) to conduct the first randomized controlled trial of PF-03654764 in allergic rhinitis. 64 participants were randomized in a double-blind, placebo-controlled 4-period crossover study. Participants were exposed to ragweed pollen for 6 hours post-dose in the EEU. The primary objective was to compare the effect of PF-03654764 + fexofe"],"journal":["Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology"],"pagination":["33"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4094756"],"repository":["biostudies-literature"],"pubmed_title":["Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit."],"pmcid":["PMC4094756"],"pubmed_authors":["North ML","Steacy LM","Hackman F","Ellis AK","Allan RJ","Hobsbawn BG","Sun X","Day AG","Walker TJ"],"additional_accession":[]},"is_claimable":false,"name":"Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit.","description":"<h4>Background</h4>Oral antihistamines that target the histamine receptor-1, such as fexofenadine, offer suboptimal relief of allergic rhinitis-associated nasal congestion. Combinations with oral sympathomimetics, such as pseudoephedrine, relieve congestion but produce side effects. Previous animal and human studies with histamine receptor-3 antagonists, such as PF-03654764, demonstrate promise.<h4>Methods</h4>Herein we employ the Environmental Exposure Unit (EEU) to conduct the first randomized controlled trial of PF-03654764 in allergic rhinitis. 64 participants were randomized in a double-blind, placebo-controlled 4-period crossover study. Participants were exposed to ragweed pollen for 6 hours post-dose in the EEU. The primary objective was to compare the effect of PF-03654764 + fexofe","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014","modification":"2026-04-29T12:39:39.158Z","creation":"2019-03-27T01:31:56Z"},"accession":"S-EPMC4094756","cross_references":{"pubmed":["25024716"],"doi":["10.1186/1710-1492-10-33"]}}